Rifamycin-derived antibiotic (non-aminoglycoside, non-systemic) · Antibiotic
Also known as Rifaximin alfa
KDIGO 2024 + manufacturer label
322 branded formulations. Look up specific brands in the Drugs workspace.
Binds to beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting transcription and protein synthesis. Bactericidal against Gram-positive and Gram-negative aerobes and anaerobes. Poor oral absorption results in high gut lumen concentrations with minimal systemic exposure.
Animal studies show no harm; limited human data - use if benefits outweigh risks
Minimal systemic absorption makes transfer to breast milk unlikely; compatible with breastfeeding
Increased systemic absorption and exposure to rifaximin, potentially leading to increased risk of rifaximin-related systemic adverse effects.
Monitor for systemic adverse effects of rifaximin, especially in patients with impaired liver function. The clinical significance of increased systemic rifaximin exposure is generally low due to its poor absorption, but caution is warranted with P-gp inhibitors.
Increased systemic absorption and exposure to rifaximin, potentially leading to increased risk of rifaximin-related systemic adverse effects.
Monitor for systemic adverse effects of rifaximin, especially in patients with impaired liver function. The clinical significance of increased systemic rifaximin exposure is generally low due to its poor absorption, but caution is warranted with P-gp inhibitors.
Despite minimal absorption, rifaximin may increase cyclosporine levels via P-gp inhibition in gut
Monitor cyclosporine levels when co-prescribing
Source: Kimi deep-research + Cla
Increased systemic absorption and exposure to rifaximin, potentially leading to increased risk of rifaximin-related systemic adverse effects.
Monitor for systemic adverse effects of rifaximin, especially in patients with impaired liver function. The clinical significance of increased systemic rifaximin exposure is generally low due to its poor absorption, but caution is warranted with P-gp inhibitors.
Increased systemic absorption and exposure to rifaximin, potentially leading to increased risk of rifaximin-related systemic adverse effects.
Monitor for systemic adverse effects of rifaximin, especially in patients with impaired liver function. The clinical significance of increased systemic rifaximin exposure is generally low due to its poor absorption, but caution is warranted with P-gp inhibitors.
Increased systemic absorption and exposure to rifaximin, potentially leading to increased risk of rifaximin-related systemic adverse effects.
Monitor for systemic adverse effects of rifaximin, especially in patients with impaired liver function. The clinical significance of increased systemic rifaximin exposure is generally low due0 to its poor absorption, but caution is warranted with P-gp inhibitors.
Increased systemic absorption and exposure to rifaximin, potentially leading to increased risk of rifaximin-related systemic adverse effects.
Monitor for systemic adverse effects of rifaximin, especially in patients with impaired liver function. The clinical significance of increased systemic rifaximin exposure is generally low due to its poor absorption, but caution is warranted with potent P-gp inhibitors.
Increased systemic absorption and exposure to rifaximin, potentially leading to increased risk of rifaximin-related systemic adverse effects.
Monitor for systemic adverse effects of rifaximin, especially in patients with impaired liver function. The clinical significance of increased systemic rifaximin exposure is generally low due to its poor absorption, but caution is warranted with P-gp inhibitors.
4 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF, Nelson·Verified: 2026-05-19 · House clinical team·Cockpit curated: 2026-05-19